Drugs / ISIS 14803
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00062816 | Jun 2003 → Jan 2004 | chronic hepatitis C virus infection | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00035945 | Oct 2001 → May 2004 | chronic hepatitis C virus infection | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISIS 14803 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00035945 ↗ |
| Route | Intravenous | “administered for up to 12 weeks by intravenous infusions” NCT00035945 ↗ |